v3.25.2
Unaudited Condensed Consolidated Interim Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Statement Line Items [Line Items]        
Revenue $ 37 $ 154 $ 37 $ 205
Research and development (2,165) (2,752) (4,321) (5,588)
General and administrative (2,212) (1,983) (3,924) (3,594)
Operating loss (4,340) (4,581) (8,208) (8,977)
Finance income 546 220 3,039 5,838
Finance expenses (1,232) (2,036) (1,629) (2,282)
Net loss before tax (5,026) (6,397) (6,798) (5,421)
Income tax benefit 195 199 387 417
Net loss for the period (4,831) (6,198) (6,411) (5,004)
Net loss attributable to shareholders of Evaxion Biotech A/S (4,831) (6,198) (6,411) (5,004)
Other comprehensive income that may be reclassified to profit or loss in subsequent periods:        
Exchange differences on translation of foreign operations (45) 24 (78) 9
Other comprehensive income that will not be reclassified to profit or loss in subsequent periods:        
Exchange differences on currency translation to presentation currency 714 4 597 101
Other comprehensive income for the period, net of tax 669 28 519 110
Total comprehensive loss (4,162) (6,170) (5,892) (4,894)
Total comprehensive loss attributable to shareholders of Evaxion Biotech A/S $ (4,162) $ (6,170) $ (5,892) $ (4,894)
Loss per share – basic and diluted (in dollars per share) $ (0.02) $ (0.12) $ (0.03) $ (0.1)